This review discusses nanotechnology's role in activating systemic anti-tumor immunity, indicating a new therapeutic approach.
This review argues that the field is advancing from circumventing to reversing and ultimately leveraging limitations to activate systemic anti-tumor immunity. This perspective offers a powerful new lens to view current and future developments.
No takes yet. Share an insight, caveat, or question.
Aili et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: